Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.49 AUD | -3.92% | -7.55% | -26.32% |
04-19 | INOVIQ Concludes Analytical Validation for Ovarian Cancer Blood Test | MT |
04-15 | Fears of Middle East Conflict Escalation Quell Appetite for Australian Shares | MT |
Valuation
Fiscal Period: Juni | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Capitalization 1 | 78.22 | 46.93 | - | - |
Enterprise Value (EV) 1 | 78.22 | 39.83 | 37.53 | 36.43 |
P/E ratio | -8.72 x | -5.48 x | -11.3 x | - |
Yield | - | - | - | - |
Capitalization / Revenue | - | 29.3 x | 7.33 x | 3.5 x |
EV / Revenue | - | 24.9 x | 5.86 x | 2.72 x |
EV / EBITDA | - | -5.53 x | -10.1 x | 33.1 x |
EV / FCF | - | -5.17 x | -9.62 x | 40.5 x |
FCF Yield | - | -19.3% | -10.4% | 2.47% |
Price to Book | - | 2.55 x | 2.55 x | 2.55 x |
Nbr of stocks (in thousands) | 92,019 | 92,019 | - | - |
Reference price 2 | 0.8500 | 0.5100 | 0.5100 | 0.5100 |
Announcement Date | 29/08/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: Juni | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net sales 1 | - | 1.6 | 6.4 | 13.4 |
EBITDA 1 | - | -7.2 | -3.7 | 1.1 |
EBIT 1 | - | -8.5 | -5 | - |
Operating Margin | - | -531.25% | -78.12% | - |
Earnings before Tax (EBT) 1 | - | -8.5 | -5 | - |
Net income 1 | -8.969 | -8.5 | -5 | - |
Net margin | - | -531.25% | -78.12% | - |
EPS 2 | -0.0975 | -0.0930 | -0.0450 | - |
Free Cash Flow 1 | - | -7.7 | -3.9 | 0.9 |
FCF margin | - | -481.25% | -60.94% | 6.72% |
FCF Conversion (EBITDA) | - | - | - | 81.82% |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 29/08/23 | - | - | - |
Balance Sheet Analysis
Fiscal Period: Juni | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net Debt 1 | - | - | - | - |
Net Cash position 1 | - | 7.1 | 9.4 | 10.5 |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow 1 | - | -7.7 | -3.9 | 0.9 |
ROE (net income / shareholders' equity) | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets 1 | - | - | - | - |
Book Value Per Share 2 | - | 0.2000 | 0.2000 | 0.2000 |
Cash Flow per Share 2 | - | -0.0600 | -0.0300 | - |
Capex 1 | - | 0.5 | 0.2 | 0.2 |
Capex / Sales | - | 31.25% | 3.12% | 1.49% |
Announcement Date | 29/08/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-26.32% | 30.48M | |
+0.67% | 42.4B | |
+46.73% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |
- Stock Market
- Equities
- IIQ Stock
- Financials INOVIQ Ltd